EP0330665A1 - Hydrosoluble ubidecarenones derivatives and their preparation - Google Patents

Hydrosoluble ubidecarenones derivatives and their preparation

Info

Publication number
EP0330665A1
EP0330665A1 EP87907217A EP87907217A EP0330665A1 EP 0330665 A1 EP0330665 A1 EP 0330665A1 EP 87907217 A EP87907217 A EP 87907217A EP 87907217 A EP87907217 A EP 87907217A EP 0330665 A1 EP0330665 A1 EP 0330665A1
Authority
EP
European Patent Office
Prior art keywords
ubidecarenones
acyl
amino
derivatives
hydrosoluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP87907217A
Other languages
German (de)
French (fr)
Inventor
Vincenzo Zappia
Mario De Rosa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0330665A1 publication Critical patent/EP0330665A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A61K8/355—Quinones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Definitions

  • Hydrosoluble ubidecarenones derivates and their preparation.
  • the present invention relates to pharmaceutica preparations containing soluble ubidecarenones prepared b disperding in acqueous media mixtures having differen ratios of ubidecarenones and acyl derivatives of 2-amino- ethansulphonic acid.
  • the ubidecarenones form an important class of lipo- soluble vitaminic principles, particularly 2,3-dimethoxy- 5-methyl-8-decaprenyl-l,4-benzoquinone, known as ubideca- renone-10, localized at the mitochondrial level, plays a key-role in mammals in the electron-transfer system and more generally in the energy production.
  • the ubiquinone-10 is widely used in a large number of cardiac pathologies, protecting the myocardium from ischemic phe- nomena and preserving the functions thereof.
  • the drug is generally administered by the oral route in form of franules, tablets and soft capsules, generally at a dosage of 10 mg.
  • the experiments carried out show a critical role of the administration form in the drug's absorption, which is usually slight.
  • biocompatible hydrosoluble formulation is therefore particularly desired.
  • the development of biocompatible, hydrosoluble formulations is of particular interest for a better bio- availability of ubidecarenone-10 both in the pharmaceuti ⁇ cal and cosmetic use.
  • the present invention concerns the development of a sys.tem able to carry in aqueous media the ubidecarenones, thanks to the interaction with amphipatic ions of general formula RNH-CH -CH -SO , wherein R is an acyl radical having more than 5 carbon atoms, preferably a natural fatty acid of the normal, iso, an eiso series or cycloal- kyl, saturated or unsaturated having from 8 to 26 carbon atoms.
  • This class of amphipatic molecules is surprisingly able to carry the ubidecarenones in water, in form of micellar and/or liposomial aggregates, even using an equi- molar ratio of the two compounds.
  • a molar excess of the amphipatic solubilizing spe- cies is preferably used, from 2 to 4 times higher than the vitamin, said conditions granting a better and faster solubilization.
  • hydrosoluble ubidecarenones may be carried out in different ways, for instance by sonica- ting an acqueous solution of the amphipatic species, to which the ubidecarenone is added or preferably by dispers ⁇ ing in water, under vigorous stirring, a mixture of ubide ⁇ carenone and N-acyl-2-amino-ethanesulphonate, prepared by evaporation of a solution of the two compounds in an orga- nic solvent, in which both are soluble.
  • micellar and/or liposomial systems so prepared are stable over long periods of time, even at extremely low or high environmental temperatures, that may be more ⁇ over lyophilized, yielding generally materials of waxy consistency, easily soluble in water by simple stirring.
  • Important characteristics of the invention, under the pharmaceutical profile are: a) the stability in time of the micellar and/or liposomial aggregates, formed by combining in aqueous solution ubidecarenones and N-acyl-2-amino-ethanesulphonates; b) the low toxicity of the solubilizing agent, which is biodegradable and metabolizable, because derived from the formation of an amide bond, which may be cleaved by amidases present in the body, said bond linking a fatty acid to 2-amino-ethanesulphonic acid, both naturally present metabolites in man; c) an improved bioavailability of ubidecarenone both by the oral and injection route; d) an improved stability of ubi
  • compositions containing as the active principle compounds of ubidecarenone and N-acyl-2-amino-ethanesulphonates optionally in admixture with conventional excipients.
  • composition of the invention may be used in the pharmacological use in many fields and particularly as myocardioenergetics, indicated in the alterations of the myocardium characterized by reduced inotropism: senile myocardiosclerosis, congestive heart failure, chronic pulmonary heart, in combination with digitalis and other cardiotonics; as adjuvant in the treatment of acute and chronic ischemic cardiopathies and of the arterial hyper- tension, prevention of cardiac damages due to the use of some cardiotoxic antitumoral agents (adriamycin and dauno- mycin) .
  • compositions of the inven ⁇ tion may moreover comprise other active principles having complementary activity.
  • T Thhee HH--NNMMRR ssppectrum in CDC1 shows the signal of the acyl moiety, in the correct integration ratio, at o 5.3; 2.4; 1.9; I.r.: 1.3 and 0.9 and those of 2-amino- ethanesulphonate at S 3.7 and 4.6.
  • the obtained biphasic system after sonication, yields an homogeneous phase of micellar and/or liposomial kind, stable in time and to the environmental parameters. For instance, freezing of the solution or its heating do not change the chemico-physical state of the dispersed supermolecular aggregates.
  • EXAMPLE 2 87.5 g of 2-amino-ethanesulphonate, suspended in 500 ml of anhydrous pyridine, were reacted at 50°C for 10 hours with 311 g of linolenic acid chloride.
  • EXAMPLE 3 43.1 g of ubidecarenone-10 and 64.2 g of arachido- nyl-2-amino-ethanesulphonate were dissolved in 1 1 of CHC1 .
  • micellar and/or liposomial system After removal of the solvent, 2 1 of water were added under vigorous stirring, till the formation of a stable micellar and/or liposomial system. After freezing and lyophilization of the solution a waxy compound orange in colour, readily soluble in the presence of water, was obtained.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Des ubidécarénones sont efficacement dissous dans des milieux aqueux au moyen de N-acyl-2-amino-éthanesulfonates, dans lesquels les résidus acyle possèdent plus de 5 atomes de carbone. Des compositions pharmaceutiques contenant des ubidécarénones ainsi solubilisés sont particulièrement efficaces en tant que produits myocardio-énergétiques.Ubidecarenones are efficiently dissolved in aqueous media using N-acyl-2-aminoethanesulfonates, in which acyl residues have more than 5 carbon atoms. Pharmaceutical compositions containing ubidecarenones thus solubilized are particularly effective as myocardioenergetic products.

Description

Λ-
Hydrosoluble ubidecarenones derivates and their preparation.
The present invention relates to pharmaceutica preparations containing soluble ubidecarenones prepared b disperding in acqueous media mixtures having differen ratios of ubidecarenones and acyl derivatives of 2-amino- ethansulphonic acid.
The ubidecarenones form an important class of lipo- soluble vitaminic principles, particularly 2,3-dimethoxy- 5-methyl-8-decaprenyl-l,4-benzoquinone, known as ubideca- renone-10, localized at the mitochondrial level, plays a key-role in mammals in the electron-transfer system and more generally in the energy production.
Because of said important metabolic roles, the ubiquinone-10 is widely used in a large number of cardiac pathologies, protecting the myocardium from ischemic phe- nomena and preserving the functions thereof.
Because of its complete insolubility in aqueous media the drug is generally administered by the oral route in form of franules, tablets and soft capsules, generally at a dosage of 10 mg. The experiments carried out show a critical role of the administration form in the drug's absorption, which is usually slight.
The availability of biocompatible hydrosoluble formulation is therefore particularly desired. The development of biocompatible, hydrosoluble formulations is of particular interest for a better bio- availability of ubidecarenone-10 both in the pharmaceuti¬ cal and cosmetic use.
The present invention concerns the development of a sys.tem able to carry in aqueous media the ubidecarenones, thanks to the interaction with amphipatic ions of general formula RNH-CH -CH -SO , wherein R is an acyl radical having more than 5 carbon atoms, preferably a natural fatty acid of the normal, iso, an eiso series or cycloal- kyl, saturated or unsaturated having from 8 to 26 carbon atoms. This class of amphipatic molecules is surprisingly able to carry the ubidecarenones in water, in form of micellar and/or liposomial aggregates, even using an equi- molar ratio of the two compounds.
A molar excess of the amphipatic solubilizing spe- cies is preferably used, from 2 to 4 times higher than the vitamin, said conditions granting a better and faster solubilization.
The preparation of hydrosoluble ubidecarenones may be carried out in different ways, for instance by sonica- ting an acqueous solution of the amphipatic species, to which the ubidecarenone is added or preferably by dispers¬ ing in water, under vigorous stirring, a mixture of ubide¬ carenone and N-acyl-2-amino-ethanesulphonate, prepared by evaporation of a solution of the two compounds in an orga- nic solvent, in which both are soluble.
The micellar and/or liposomial systems so prepared are stable over long periods of time, even at extremely low or high environmental temperatures, that may be more¬ over lyophilized, yielding generally materials of waxy consistency, easily soluble in water by simple stirring. Important characteristics of the invention, under the pharmaceutical profile, are: a) the stability in time of the micellar and/or liposomial aggregates, formed by combining in aqueous solution ubidecarenones and N-acyl-2-amino-ethanesulphonates; b) the low toxicity of the solubilizing agent, which is biodegradable and metabolizable, because derived from the formation of an amide bond, which may be cleaved by amidases present in the body, said bond linking a fatty acid to 2-amino-ethanesulphonic acid, both naturally present metabolites in man; c) an improved bioavailability of ubidecarenone both by the oral and injection route; d) an improved stability of ubidecarenones towards undesi- red degradative processes; e) a more effective therapeutic action in comparison to the formulations presently marketed.
The invention provides therefore pharmaceutical compositions containing as the active principle compounds of ubidecarenone and N-acyl-2-amino-ethanesulphonates optionally in admixture with conventional excipients.
The composition of the invention may be used in the pharmacological use in many fields and particularly as myocardioenergetics, indicated in the alterations of the myocardium characterized by reduced inotropism: senile myocardiosclerosis, congestive heart failure, chronic pulmonary heart, in combination with digitalis and other cardiotonics; as adjuvant in the treatment of acute and chronic ischemic cardiopathies and of the arterial hyper- tension, prevention of cardiac damages due to the use of some cardiotoxic antitumoral agents (adriamycin and dauno- mycin) .
The daily theraperutic dose, the administration route and frequency depend on various factors (diagnosis, patient's conditions, etc.), but they will be anyhow easi¬ ly determined, case by case, absolutely in non-critical way as a consequence, inter alia, of the very low toxicity of the system components. The compositions of the inven¬ tion may moreover comprise other active principles having complementary activity.
The procedures generally described in the present invention, because of their simplicity or limited cost, are easily suited to the development of preparative pro¬ cesses on the industrial scale. The following examples illustrate the preparation of different kinds of soluble ubidecarenones. They necessarily concern only some of the numerous possibilities which can be envisaged and, without any limitative character, they only define the scope of the invention. EXAMPLE 1
62.5 g of 2-amino-ethansulphonate, suspended in 500 ml of anhydrous dimethylformamide, were reacted at 70°C for 10 hours with 410 g of oleic anhydride, in the presen¬ ce of 0.5 g of dimethylami opyridine as a catalyst. After evaporation of the solvent under vacuo, the oily residue was repeatedly triturated in ethyl ether. 190 g of N-oleyl-2-amino-ethansulphonate as a waxy, white solid, were obtained.
2 2
T Thhee HH--NNMMRR ssppectrum in CDC1 shows the signal of the acyl moiety, in the correct integration ratio, at o 5.3; 2.4; 1.9; I.r.: 1.3 and 0.9 and those of 2-amino- ethanesulphonate at S 3.7 and 4.6.
86.2 g of ubidecarenone-10 were added to 81 g of N-oleyl-2-aminoethansulphonate, dissolved in 2.8 liters of water.
The obtained biphasic system, after sonication, yields an homogeneous phase of micellar and/or liposomial kind, stable in time and to the environmental parameters. For instance, freezing of the solution or its heating do not change the chemico-physical state of the dispersed supermolecular aggregates.
EXAMPLE 2 87.5 g of 2-amino-ethanesulphonate, suspended in 500 ml of anhydrous pyridine, were reacted at 50°C for 10 hours with 311 g of linolenic acid chloride.
After evaporation of the solvent under vacuo, the oily residue was first triturated in ethyl ether and then, dissolved in water, was dialyzed against water. After lyophilization 255 g of N-linoleyl-2-amino-ethanesulphona- te as a white, waxy solid, were obtained. The H -NMR spectrum recorded in CDC1 shows, in the correct integra¬ tion ratios the signals of the acyl moiety at S 5.3; 2.8; 2.4; 1.9;1.6;1.3;0.9 and those of 2-amino-ethanesulphonate at S 3.7 and 4.6. 172 g of ubidecarenone-10 and 321 g of N-linoleyl- 2-amino-ethanesulphonate were dissolved in 2 1 of 1 CHC1 . After evaporation of the solvent under vacuum, 3.4 liters of water were added under vigorous stirring. An homogeneous system, yellow-orange in colour, of micellar and/or liposomial kind, stable in time and to the environ- mental parameters was obtained.
EXAMPLE 3 43.1 g of ubidecarenone-10 and 64.2 g of arachido- nyl-2-amino-ethanesulphonate were dissolved in 1 1 of CHC1 .
After removal of the solvent, 2 1 of water were added under vigorous stirring, till the formation of a stable micellar and/or liposomial system. After freezing and lyophilization of the solution a waxy compound orange in colour, readily soluble in the presence of water, was obtained.

Claims

1. Hydrosoluble ubidecarenones derivatives obtained by addition to the ubidecarenones of N-acyl-2-amino-ethane- sulphonate wherein the acyl residue has more than 5 carbon atoms and is preferably a natural fatty acid, saturated or unsaturated of the normal, iso, anteiso or cycloalkyl series, having from 8 to 26 carbon atoms.
2. A process for the preparation of the derivatives of claim 1, characterized in that ubidecarenones are subjected to sonication in acqueous solutions of N-acyl-2-amino- ethanesulphonates, generally used in a stoichiometric ratio with respect to the ubidecarenone higher than 1:1 (moles of ubidecarenones/moles of N-acyl-2-amino-ethane- sulphonate), preferably 1:2-4.
3. A process for the preparation of the derivatives of claim 1, characterized in that a mixture of ubidecarenone and N-acyl-2-amino-ethanesulphonate (molar ratio from 1:1 to 1:4), obtained by evaporation of a solution of the two compounds in an organic solvent in which both are soluble, is subjected to mechanical dispersion.
4. Pharmaceutical compositions containing as the acti¬ ve principle an hydrosoluble ubidecarenone derivative according to claim 1, in admixture with the usual exci- pients and vehicles.
EP87907217A 1986-10-23 1987-10-19 Hydrosoluble ubidecarenones derivatives and their preparation Withdrawn EP0330665A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2210586 1986-10-23
IT8622105A IT1214540B (en) 1986-10-23 1986-10-23 WATER SOLUBLE FORMULATIONS OF UBIDECARENONES, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT COMPOSE THEM.

Publications (1)

Publication Number Publication Date
EP0330665A1 true EP0330665A1 (en) 1989-09-06

Family

ID=11191567

Family Applications (1)

Application Number Title Priority Date Filing Date
EP87907217A Withdrawn EP0330665A1 (en) 1986-10-23 1987-10-19 Hydrosoluble ubidecarenones derivatives and their preparation

Country Status (4)

Country Link
EP (1) EP0330665A1 (en)
AU (1) AU8174887A (en)
IT (1) IT1214540B (en)
WO (1) WO1988003019A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032457A (en) * 1988-03-03 1991-07-16 Micro Vesicular Systems, Inc. Paucilamellar lipid vesicles using charge-localized, single chain, nonphospholipid surfactants
PT2544663T (en) 2010-03-12 2018-04-05 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2537914C3 (en) * 1975-08-26 1979-09-13 Bayer Ag, 5090 Leverkusen Process for the preparation of acyl taurides
JPS588010A (en) * 1981-07-08 1983-01-18 Eisai Co Ltd Ubidecarenone-containing ribosome
IL79114A (en) * 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8803019A1 *

Also Published As

Publication number Publication date
AU8174887A (en) 1988-05-25
IT8622105A0 (en) 1986-10-23
WO1988003019A1 (en) 1988-05-05
IT1214540B (en) 1990-01-18

Similar Documents

Publication Publication Date Title
JP3179494B2 (en) Soluble analog of probucol
JPH0692399B2 (en) Complex of flavanolignan and phospholipid, method for producing the same, and pharmaceutical composition for treating liver disease
JP2005523305A (en) Inclusion compound of fumagillol derivative or salt thereof, and pharmaceutical composition containing the inclusion compound
KR100264369B1 (en) Chalcones and esters thereof with antiproliferative activity in uterus, ovary and breast tumours and pharmaceutical preparation containing them
US4883670A (en) Cosmetic preparations containing ubidecarenones
US5116949A (en) Benzoyl urea compound-albumin complex
JPS638339A (en) Medicinal composition for non-oral administration
EP0330665A1 (en) Hydrosoluble ubidecarenones derivatives and their preparation
EP0165123A2 (en) Lipophile derivatives of muramyl peptides having macrophage-activating properties, compositions containing them and processes for obtaining them
KR930019212A (en) Phisostigmine derivatives and uses thereof and pharmaceutical preparations containing them
JPH02223525A (en) Arterialization inhibitor
BE1001704A3 (en) Aqueous compositions containing acid derivative piperidinylcyclopentylheptenoique.
JP4130700B2 (en) Antitumor agent-containing composition
EP0239332B1 (en) A pharmaceutical formulation containing indomethacin
US5420124A (en) Stable, painless piroxicam potassium injectable composition
US5610160A (en) Topical 5-fluorouracil prodrug composition and method
CA2645327A1 (en) Use of (3s)-n-hydroxy-4-({4-[(4-hydroxy-2-butynyl)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide or (s)-n-hydroxy-4-(4-but-2-ynyloxy-benzenesulfonyl) -2,2-dimethyl-thiomorpholine -3-carboxamide for treating inflammatory skin pathologies
JP2631688B2 (en) Pharmaceuticals composed of glycyrrhetinic acid derivatives
KR20040022224A (en) A group of novel anti-cancer compounds with specipic structure
Ansbacher et al. Water-Soluble antihemorrhagic compounds
KR100344099B1 (en) Novel biphenyldicarboxylate derivative and method for manufacturing the same
RU2135474C1 (en) Salts of 1-deoxy-1-n-methylaminohexaalcohols with n-acridone acetic acid showing immunomodulating activity and drugs on their base
JPS5821888B2 (en) Suiseirafu oxanide seizai
EP0449722B1 (en) New complexes of tiaprofenic acid or its insoluble or partially soluble esters with cyclodextrines or their derivates
US4271150A (en) Urokinase preparation for oral administration

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19890419

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19900502